140 related articles for article (PubMed ID: 25932631)
1. The Structure of the T190M Mutant of Murine α-Dystroglycan at High Resolution: Insight into the Molecular Basis of a Primary Dystroglycanopathy.
Bozzi M; Cassetta A; Covaceuszach S; Bigotti MG; Bannister S; Hübner W; Sciandra F; Lamba D; Brancaccio A
PLoS One; 2015; 10(5):e0124277. PubMed ID: 25932631
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycosylation of dystroglycan due to T192M mutation: a molecular insight behind the fact.
Bhattacharya S; Das A; Ghosh S; Dasgupta R; Bagchi A
Gene; 2014 Mar; 537(1):108-14. PubMed ID: 24361964
[TBL] [Abstract][Full Text] [Related]
3. The effect of the pathological V72I, D109N and T190M missense mutations on the molecular structure of α-dystroglycan.
Covaceuszach S; Bozzi M; Bigotti MG; Sciandra F; Konarev PV; Brancaccio A; Cassetta A
PLoS One; 2017; 12(10):e0186110. PubMed ID: 29036200
[TBL] [Abstract][Full Text] [Related]
4. α-Dystroglycan hypoglycosylation affects cell migration by influencing β-dystroglycan membrane clustering and filopodia length: A multiscale confocal microscopy analysis.
Palmieri V; Bozzi M; Signorino G; Papi M; De Spirito M; Brancaccio A; Maulucci G; Sciandra F
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2182-2191. PubMed ID: 28572004
[TBL] [Abstract][Full Text] [Related]
5. A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients.
Humphrey EL; Lacey E; Le LT; Feng L; Sciandra F; Morris CR; Hewitt JE; Holt I; Brancaccio A; Barresi R; Sewry CA; Brown SC; Morris GE
Neuromuscul Disord; 2015 Jan; 25(1):32-42. PubMed ID: 25387694
[TBL] [Abstract][Full Text] [Related]
6. Insights from molecular dynamics simulations: structural basis for the V567D mutation-induced instability of zebrafish alpha-dystroglycan and comparison with the murine model.
Pirolli D; Sciandra F; Bozzi M; Giardina B; Brancaccio A; De Rosa MC
PLoS One; 2014; 9(7):e103866. PubMed ID: 25078606
[TBL] [Abstract][Full Text] [Related]
7. The structure of the N-terminal region of murine skeletal muscle alpha-dystroglycan discloses a modular architecture.
Bozic D; Sciandra F; Lamba D; Brancaccio A
J Biol Chem; 2004 Oct; 279(43):44812-6. PubMed ID: 15326183
[TBL] [Abstract][Full Text] [Related]
8. Limb-girdle muscular dystrophy type 2I is not rare in Taiwan.
Liang WC; Hayashi YK; Ogawa M; Wang CH; Huang WT; Nishino I; Jong YJ
Neuromuscul Disord; 2013 Aug; 23(8):675-81. PubMed ID: 23800702
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
[TBL] [Abstract][Full Text] [Related]
10. A dystroglycan mutation associated with limb-girdle muscular dystrophy.
Hara Y; Balci-Hayta B; Yoshida-Moriguchi T; Kanagawa M; Beltrán-Valero de Bernabé D; Gündeşli H; Willer T; Satz JS; Crawford RW; Burden SJ; Kunz S; Oldstone MB; Accardi A; Talim B; Muntoni F; Topaloğlu H; Dinçer P; Campbell KP
N Engl J Med; 2011 Mar; 364(10):939-46. PubMed ID: 21388311
[TBL] [Abstract][Full Text] [Related]
11. A second Ig-like domain identified in dystroglycan by molecular modelling and dynamics.
De Rosa MC; Pirolli D; Bozzi M; Sciandra F; Giardina B; Brancaccio A
J Mol Graph Model; 2011 Aug; 29(8):1015-24. PubMed ID: 21605994
[TBL] [Abstract][Full Text] [Related]
12. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
[TBL] [Abstract][Full Text] [Related]
13. Probing the stability of the "naked" mucin-like domain of human α-dystroglycan.
Bozzi M; Di Stasio E; Scaglione GL; Desiderio C; Martelli C; Giardina B; Sciandra F; Brancaccio A
BMC Biochem; 2013 Jul; 14():15. PubMed ID: 23815856
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of expression of dystroglycan may protect the heart.
Brancaccio A
Neuromuscul Disord; 2013 Nov; 23(11):867-70. PubMed ID: 23911074
[TBL] [Abstract][Full Text] [Related]
15. A dystroglycan mutation (p.Cys667Phe) associated to muscle-eye-brain disease with multicystic leucodystrophy results in ER-retention of the mutant protein.
Signorino G; Covaceuszach S; Bozzi M; Hübner W; Mönkemöller V; Konarev PV; Cassetta A; Brancaccio A; Sciandra F
Hum Mutat; 2018 Feb; 39(2):266-280. PubMed ID: 29134705
[TBL] [Abstract][Full Text] [Related]
16. In-silico structural analysis of E509K mutation in LARGE and T192M mutation in Alpha Dystroglycan in the inhibition of glycosylation of Alpha Dystroglycan by LARGE.
Bhattacharya S; Das A; Bagchi A
Comput Biol Chem; 2016 Oct; 64():313-321. PubMed ID: 27565399
[TBL] [Abstract][Full Text] [Related]
17. Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane.
Yoshida-Moriguchi T; Campbell KP
Glycobiology; 2015 Jul; 25(7):702-13. PubMed ID: 25882296
[TBL] [Abstract][Full Text] [Related]
18. Molecular recognition by LARGE is essential for expression of functional dystroglycan.
Kanagawa M; Saito F; Kunz S; Yoshida-Moriguchi T; Barresi R; Kobayashi YM; Muschler J; Dumanski JP; Michele DE; Oldstone MB; Campbell KP
Cell; 2004 Jun; 117(7):953-64. PubMed ID: 15210115
[TBL] [Abstract][Full Text] [Related]
19. Characterization of site-specific O-glycan structures within the mucin-like domain of alpha-dystroglycan from human skeletal muscle.
Nilsson J; Nilsson J; Larson G; Grahn A
Glycobiology; 2010 Sep; 20(9):1160-9. PubMed ID: 20507882
[TBL] [Abstract][Full Text] [Related]
20. The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies.
Brockington M; Muntoni F
Acta Myol; 2005 Dec; 24(3):217-21. PubMed ID: 16629056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
